Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Relmada Therapeutics (NASDAQ:RLMD) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09, FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV-01 remains on track for registrational development: Relmada plans to file the IND by year-end 2026 and begin the Phase III rescue program after clearance, with approximately 80 clinical sites prepared and 60 designated as primary sites.
• Phase II results support NDV-01’s potential: The company reported a 95% complete response rate at any time and a 76% durable complete response rate at 12 months, with favorable safety and tolerability.
• Manufacturing is the key near-term execution risk. Formulation, process development, and analytical work are complete, but Relmada still needs to secure GMP manufacturing capacity, produce batches, and generate sufficient stability data before filing the IND.
• Relmada reported substantial financial runway: Cash, cash equivalents, and short-term investments totaled $217.7 million at quarter-end, which management expects to fund operations through 2029, including completion of the NDV-01 Phase III rescue program.
• The company has not yet finalized the timing or format of additional clinical disclosures; management suggested that six-month data and a larger patient sample may be more meaningful than the previously anticipated three-month results, potentially shifting disclosure into the first half of 2027.

Relmada Therapeutics Price Performance

NASDAQ:RLMD traded down $0.43 during mid-day trading on Friday, reaching $4.94. 2,125,013 shares of the company’s stock traded hands, compared to its average volume of 1,542,462. Relmada Therapeutics has a 12-month low of $0.55 and a 12-month high of $8.00. The firm has a market capitalization of $518.16 million, a price-to-earnings ratio of -5.49 and a beta of 0.46. The company has a 50 day moving average price of $6.05 and a 200-day moving average price of $5.93.

Analysts Set New Price Targets

Several brokerages have weighed in on RLMD. HC Wainwright assumed coverage on Relmada Therapeutics in a research report on Thursday, June 18th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Hedge Funds Weigh In On Relmada Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RLMD. XTX Topco Ltd purchased a new position in shares of Relmada Therapeutics during the second quarter valued at about $28,000. Goldman Sachs Group Inc. purchased a new stake in Relmada Therapeutics in the first quarter worth about $33,000. LMR Partners LLP purchased a new stake in Relmada Therapeutics in the second quarter worth about $33,000. Schonfeld Strategic Advisors LLC bought a new stake in Relmada Therapeutics during the 4th quarter valued at approximately $64,000. Finally, Jane Street Group LLC purchased a new position in shares of Relmada Therapeutics during the 2nd quarter worth approximately $69,000. Institutional investors own 45.24% of the company’s stock.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.